Amgen, Cytokinetics heart failure drug misses goal in study Reuters AMSTERDAM (Reuters) - An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain. Shares in Cytokinetics fell 17 percent in pre-market ... Amgen, Cytokinetics Report Mixed Results For Heart Failure Drug Despite missing primary efficacy endpoint, ATOMIC-AHF identifies positive trends Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ... |
